青光眼滤过术后抗瘢痕药物研究进展
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Recent advances in anti-scarring agents for glaucoma filtration surgery
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    青光眼是临床常见致盲眼病,目前以手术治疗为主,但术后复发率较高,主要原因是术区成纤维细胞增生,致瘢痕形成阻塞滤过道。为提高手术成功率,一些抗瘢痕形成的药物被越来越多的应用于青光眼滤过手术的实验与临床研究中,但这些药物也有一定的并发症及毒副作用。随着医疗技术的进步,人们正在寻找更为安全有效的给药方式和新的抑制瘢痕形成的药物。 

    Abstract:

    Glaucoma is a common clinical blinding eye disease, currently surgery is the principal way, but the recurrence rate after surgery is still high, the main reason is fibroblasts in the operation area, which lead to scar formation blocking filtration road. To improve the success rate of surgery, a number of anti-cicatricial drugs are increasingly being applied in glaucoma filtration surgery in experimental and clinical studies, but these drugs also have certain complications and side effects. As medical technology advances, people are looking for some safer and more effective drug delivery methods and new drugs that inhibit scar formation.

    参考文献
    相似文献
    引证文献
引用本文

甘露,唐飞,唐莉.青光眼滤过术后抗瘢痕药物研究进展.国际眼科杂志, 2012,12(8):1511-1514.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2012-04-06
  • 最后修改日期:2012-07-06
  • 录用日期:
  • 在线发布日期:
  • 出版日期:
文章二维码